Voyager Therapeutics

Yahoo Finance • 12 days ago

Voyager Presents Robust Preclinical Data from Tau Targeting Gene Therapy and Antibody Programs at AD/PD™ 2025

- Single IV administration of tau silencing gene therapy VY1706 significantly reduced tau mRNA and protein levels, with broad brain distribution and liver de-targeting, in NHP study - - Preclinical murine data strengthen case for specific... Full story

Yahoo Finance • 22 days ago

Bragar Eagel & Squire, P.C. Is Investigating Dave, Red Cat, Perpetua, and Voyager and Encourages Investors to Contact the Firm

NEW YORK, March 20, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Dave, Inc. (NASDAQ: DAVE), Red Cat Holdings, Inc. (NASDAQ: RCAT), Pe... Full story

Yahoo Finance • last month

Voyager Reports Fourth Quarter and Full Year 2024 Financial and Operating Results

- Tau silencing gene therapy VY1706 robustly reduced tau mRNA levels, with broad distribution, and was well-tolerated in NHP study; IND filing anticipated in 2026 - - Anti-tau antibody VY7523was well tolerated in healthy volunteers and sh... Full story

Yahoo Finance • last month

Voyager Therapeutics Announces Fourth Quarter 2024 Conference Call and Webcast

LEXINGTON, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will report fourth quarter 2024 financial and opera... Full story

Yahoo Finance • last month

Voyager Reports Positive Topline Data for Single Ascending Dose (SAD) Trial of Anti-Tau Antibody VY7523 and Initiates Multiple Ascending Dose (MAD) Trial in Alzheimer’s Disease

- Topline SAD data from healthy volunteers demonstrate safety, tolerability, and dose-proportional pharmacokinetics, supporting potentially best-in-class profile - - MAD study initiated in patients with early Alzheimer’s disease; initial... Full story

Yahoo Finance • 2 months ago

VOYAGER ALERT: Bragar Eagel & Squire, P.C. is Investigating Voyager Therapeutics, Inc. on Behalf of Voyager Stockholders and Encourages Investors to Contact the Firm

NEW YORK, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Voyager Therapeutics, Inc. (“Voyager” or the “Company”) (NASDAQ:VYGR)... Full story

Yahoo Finance • 2 months ago

Kirby McInerney LLP Announces Investigation Against Voyager Therapeutics, Inc. (VYGR) on Behalf of Investors

NEW YORK, Feb. 19, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Voyager Therapeutics, Inc. (“Voyager” or the “Company”) (NASDAQ:VYGR). The investigation concerns whether Voyager a... Full story

Yahoo Finance • last year

12 Best Healthcare Stocks For the Long-Term

In this piece, we will take a look at the 12 best healthcare stocks for the long term. If you want to skip our overview of the healthcare industry, then you can take a look at 5 Best Healthcare Stocks For the Long-Term. The healthcare ind... Full story

Yahoo Finance • last year

Voyager Therapeutics Reports Third Quarter 2023 Financial and Operating Results

- GLP toxicology studies initiated for VY-TAU01 anti-tau antibody for Alzheimer’s disease to enable anticipated 1H 2024 IND filing - - SOD1 ALS gene therapy program on track for development candidate selection by end of year – - Conferen... Full story

Yahoo Finance • last year

Voyager Therapeutics Announces Third Quarter 2023 Conference Call and Webcast

CAMBRIDGE, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR) a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced it will report third quarter 2023... Full story

Yahoo Finance • 2 years ago

Voyager Therapeutics to Present at the Chardan Genetic Medicines Conference

CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced that Chief Executive Officer Al... Full story

Yahoo Finance • 2 years ago

Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, has entered into employment agreements with thr... Full story

Yahoo Finance • 2 years ago

Voyager Therapeutics to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced that management will participate... Full story

Yahoo Finance • 2 years ago

Voyager Therapeutics Announces Appointment of Jacquelyn Fahey Sandell as Chief Legal Officer

CAMBRIDGE, Mass., July 10, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced the appointment of Jacquelyn Fah... Full story

Yahoo Finance • 2 years ago

Voyager Therapeutics Presents Robust, Multi-Species Results from Preclinical Studies of IV-Delivered, TRACER™-Generated Novel Capsids at the ASGCT 26th Annual Meeting

CAMBRIDGE, Mass., May 18, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, presented data today validating the ability of no... Full story

Yahoo Finance • 2 years ago

OMass Therapeutics Announces Appointment of New Board Chair and Series B Extension

PRESSRELEASE OMassTherapeuticsAnnouncesAppointmentofNewBoardChair andSeries B Extension Jim Geraghty joins as Independent Director and Chair, bringing US and international experience from Genzyme and as NED and chair of multiple listed... Full story

Yahoo Finance • 2 years ago

Voyager Therapeutics Reports First Quarter 2023 Financial and Operating Results

- Neurocrine Biosciences strategic collaboration and Novartis license option exercise demonstrate Voyager pipeline and platform value and strengthen balance sheet - - Alzheimer’s disease franchise advances: selected lead candidate for ant... Full story

Yahoo Finance • 2 years ago

Voyager Therapeutics Announces Appointment of George Scangos, Ph.D., to Board of Directors

CAMBRIDGE, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced the appointment of George Scangos... Full story

Yahoo Finance • 2 years ago

Voyager Therapeutics Announces First Quarter 2023 Conference Call and Webcast

CAMBRIDGE, Mass., May 02, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR) a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced it will report first quarter 2023... Full story

Yahoo Finance • 2 years ago

Voyager Therapeutics Presents New Data Supporting Tau Antibody Program for Alzheimer’s Disease and GBA1 Gene Therapy Program for Parkinson’s Disease at the AD/PD™ Conference

CAMBRIDGE, Mass., March 28, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today presented new data from its anti-tau anti... Full story